AstraZeneca PLC (AZN)Healthcare | Drug Manufacturers - General | Cambridge, United Kingdom | NYSE
162.84 USD
+0.14
(0.086%)
⇧
(Aug. 31, 2026, 10:58 a.m.
EDT)
|
Hot Take ↕ | Aug. 22, 2026, 1:57 a.m. EDT
The most compelling signal here is the divergence between the company's robust fundamentals and its lagging technicals. While the stock trades below its fifty-day and two-hundred-day moving averages, the recent fourteen-day price action shows a strong recovery, and the analyst consensus remains a strong buy with a target price nearly thirty percent higher than the current level. The business generates high returns on equity and maintains a healthy payout ratio, ensuring the dividend is secure despite the modest yield. For the short term, the price is testing a critical resistance zone where options activity suggests a battle between bulls and bears. For the long term, the valuation is attractive relative to growth expectations, making this a solid core holding for investors willing to overlook the temporary technical weakness. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.079496 |
| AutoETS | 0.099505 |
| AutoARIMA | 0.099965 |
| MSTL | 0.102900 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 3.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.063 |
| Excess Kurtosis | -0.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-08-06 |
| Last Dividend Date | 2026-02-18 |
| Debt to Equity Ratio | 64.225 |
| Revenue per Share | 39.591 |
| Market Cap | 252,546,252,800 |
| Trailing P/E | 24.34 |
| Forward P/E | 14.33 |
| Beta | 0.21 |
| Profit Margins | 17.02% |
| Website | https://www.astrazeneca.com |
As of Aug. 22, 2026, 1:57 a.m. EDT: Speculators are positioning a significant barrier at the 170 strike across multiple expirations, indicating a strong resistance level where buyers expect the price to stall or reverse. There is heavy call volume at 170 and 175, suggesting a bullish bias for a move above current levels. Conversely, put positioning is concentrated at the 160 strike, creating a support floor. Deep out-of-the-money puts show elevated implied volatility, hinting at fear of a sharp drop, while call speculation at 195+ suggests some traders are pricing in a larger upside move beyond the immediate resistance.
| Last Yield | 1yr Yield | 3yr Avg | 5yr Avg |
|---|---|---|---|
| 1.03% | 1.03% | 1.77% | 1.97% |
| Date | Dividend | Yield % |
|---|---|---|
| 2026-02-19 | 2.153000 | 1.032020 |
| 2025-08-08 | 1.030000 | 0.700204 |
| 2025-02-21 | 2.100000 | 1.414713 |
| 2024-08-09 | 1.000000 | 0.615839 |
| 2024-02-22 | 1.970000 | 1.535943 |
| 2023-08-10 | 0.930000 | 0.661075 |
| 2023-02-23 | 1.970000 | 1.461424 |
| 2022-08-11 | 0.930000 | 0.719258 |
| 2022-02-24 | 1.970000 | 1.694478 |
| 2021-08-12 | 0.900000 | 0.783154 |
| 2021-02-25 | 1.900000 | 1.942343 |
| 2020-08-13 | 0.900000 | 0.806452 |
| 2020-02-27 | 1.900000 | 2.107832 |
| 2019-08-08 | 0.900000 | 1.019483 |
| 2019-02-28 | 1.900000 | 2.284752 |
| 2018-08-09 | 0.900000 | 1.136077 |
| 2018-02-15 | 1.900000 | 2.792475 |
| 2017-08-09 | 0.900000 | 1.526977 |
| 2017-02-15 | 1.900000 | 3.294036 |
| 2016-08-10 | 0.900000 | 1.341282 |
| 2016-02-17 | 1.900000 | 3.160346 |
| 2015-08-12 | 0.900000 | 1.348113 |
| 2015-02-18 | 1.900000 | 2.812315 |
| 2014-08-13 | 0.900000 | 1.313869 |
| 2014-02-19 | 1.900000 | 2.888416 |
| 2013-08-14 | 0.900000 | 1.791758 |
| 2013-02-13 | 1.900000 | 4.143044 |
| 2012-08-08 | 0.900000 | 1.907184 |
| 2012-02-15 | 1.950000 | 4.312251 |
| 2011-08-04 | 0.850000 | 1.926564 |
| 2011-02-02 | 1.850000 | 3.877594 |
| 2010-08-04 | 0.700000 | 1.361868 |
| 2010-02-03 | 1.710000 | 3.801690 |
| 2009-08-05 | 0.590000 | 1.262302 |
| 2009-02-04 | 1.500000 | 3.979836 |
| 2008-08-06 | 0.550000 | 1.113811 |
| 2008-02-07 | 1.350000 | 3.486570 |
| 2007-08-08 | 0.520000 | 1.018809 |
| 2007-02-07 | 1.230000 | 2.120690 |
| 2006-08-09 | 0.490000 | 0.807914 |
| 2006-02-08 | 0.920000 | 1.985754 |
| 2005-08-10 | 0.380000 | 0.818084 |
| 2005-02-09 | 0.645000 | 1.642057 |
| 2004-08-11 | 0.295000 | 0.671676 |
| 2004-02-18 | 0.540000 | 1.114781 |
| 2003-08-20 | 0.255000 | 0.628079 |
| 2003-02-19 | 0.522000 | 1.517001 |
| 2002-08-21 | 0.256000 | 0.842105 |
| 2002-02-20 | 0.522000 | 1.050302 |
| 2001-08-22 | 0.256000 | 0.521385 |
| 2001-02-21 | 0.522000 | 1.144737 |
| 2000-11-14 | 1.073000 | 2.232510 |
| 2000-09-06 | 0.256000 | 0.580993 |
| 2000-03-08 | 0.522000 | 1.430137 |
| 1999-09-08 | 0.256000 | 0.644025 |
| 1999-04-07 | 0.350000 | 0.756757 |
| 1998-09-16 | 0.283000 | 0.722169 |
| 1998-03-18 | 0.512000 | 1.171960 |
| 1997-09-17 | 0.266333 | 0.838844 |
| 1997-03-19 | 0.447333 | 1.583480 |
| 1996-09-20 | 0.240667 | 0.980646 |
| 1996-03-22 | 0.253333 | 1.215998 |
| 1995-09-22 | 0.223667 | 1.266040 |
| 1995-03-24 | 0.350667 | 2.468038 |
| 1994-09-23 | 0.205333 | 1.589675 |
| 1994-03-18 | 0.314333 | 2.794071 |
| 1993-09-24 | 0.193000 | 1.788417 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.01446569 |
| Address1 | 1 Francis Crick Avenue |
| Address2 | Cambridge Biomedical Campus |
| All Time High | 212.71 |
| All Time Low | 8.958333 |
| Ask | 162.81 |
| Ask Size | 200 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 3,274,420 |
| Average Daily Volume3 Month | 3,077,949 |
| Average Volume | 3,077,949 |
| Average Volume10Days | 3,274,420 |
| Beta | 0.211 |
| Bid | 162.74 |
| Bid Size | 200 |
| Board Risk | 8 |
| Book Value | 32.427 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 162.84 |
| Current Ratio | 0.886 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 163.75 |
| Day Low | 161.96 |
| Debt To Equity | 64.225 |
| Display Name | AstraZeneca |
| Dividend Date | 1,788,825,600 |
| Dividend Rate | 3.2 |
| Dividend Yield | 1.96 |
| Earnings Call Timestamp End | 1,785,149,100 |
| Earnings Call Timestamp Start | 1,785,149,100 |
| Earnings Growth | 0.025 |
| Earnings Quarterly Growth | 0.023 |
| Earnings Timestamp | 1,793,390,400 |
| Earnings Timestamp End | 1,793,390,400 |
| Earnings Timestamp Start | 1,793,390,400 |
| Ebitda | 19,904,000,000 |
| Ebitda Margins | 0.32435 |
| Enterprise To Ebitda | 14.058 |
| Enterprise To Revenue | 4.56 |
| Enterprise Value | 279,804,706,816 |
| Eps Current Year | 10.05333 |
| Eps Forward | 11.36 |
| Eps Trailing Twelve Months | 6.69 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,786,060,800 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 170.8496 |
| Fifty Day Average Change | -8.009598 |
| Fifty Day Average Change Percent | -0.046880987 |
| Fifty Two Week Change Percent | 1.446569 |
| Fifty Two Week High | 212.71 |
| Fifty Two Week High Change | -49.87001 |
| Fifty Two Week High Change Percent | -0.2344507 |
| Fifty Two Week Low | 145.8 |
| Fifty Two Week Low Change | 17.039993 |
| Fifty Two Week Low Change Percent | 0.11687238 |
| Fifty Two Week Range | 145.8 - 212.71 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 737,213,400,000 |
| Five Year Avg Dividend Yield | 2.09 |
| Float Shares | 1,542,950,310 |
| Forward Eps | 11.36 |
| Forward P E | 14.334507 |
| Free Cashflow | 4,905,375,232 |
| Full Exchange Name | NYSE |
| Full Time Employees | 96,100 |
| Fullday Change | 0.13999939 |
| Fullday Change Percent | 0.08604757 |
| Fullday Price | 162.84 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.8169 |
| Gross Profits | 50,130,001,920 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00046999997 |
| Held Percent Institutions | 0.64821 |
| Implied Shares Outstanding | 1,550,885,842 |
| Industry | Drug Manufacturers - General |
| Industry Disp | Drug Manufacturers - General |
| Industry Key | drug-manufacturers-general |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,771,459,200 |
| Last Dividend Value | 2.153 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,769,990,400 |
| Last Split Factor | 1:2 |
| Long Business Summary | AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. |
| Long Name | AstraZeneca PLC |
| Market | us_market |
| Market Cap | 252,546,252,800 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_336774 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 10,446,000,128 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 255,431,983,667 |
| Number Of Analyst Opinions | 11 |
| Open | 162.7 |
| Operating Cashflow | 13,699,999,744 |
| Operating Margins | 0.23459 |
| Overall Risk | 8 |
| Payout Ratio | 0.4741 |
| Peg Ratio | 1.4 |
| Phone | 44 20 3749 5000 |
| Previous Close | 162.7 |
| Price Eps Current Year | 16.197617 |
| Price Hint | 2 |
| Price To Book | 5.0217414 |
| Price To Sales Trailing12 Months | 4.11541 |
| Profit Margins | 0.17021999 |
| Quick Ratio | 0.664 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.45455 |
| Region | US |
| Regular Market Change | 0.13999939 |
| Regular Market Change Percent | 0.08604757 |
| Regular Market Day High | 163.75 |
| Regular Market Day Low | 161.96 |
| Regular Market Day Range | 161.96 - 163.75 |
| Regular Market Open | 162.7 |
| Regular Market Previous Close | 162.7 |
| Regular Market Price | 162.84 |
| Regular Market Time | 1,788,188,309 |
| Regular Market Volume | 616,987 |
| Return On Assets | 0.080170006 |
| Return On Equity | 0.21965 |
| Revenue Growth | 0.064 |
| Revenue Per Share | 39.591 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 1,550,885,842 |
| Shares Percent Shares Out | 0.0011999999 |
| Shares Short | 1,892,646 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,533,640 |
| Short Name | AstraZeneca PLC |
| Short Percent Of Float | 0.0011999999 |
| Short Ratio | 0.49 |
| Source Interval | 15 |
| Symbol | AZN |
| Target High Price | 240.0 |
| Target Low Price | 184.0 |
| Target Mean Price | 212.53636 |
| Target Median Price | 215.0 |
| Total Cash | 4,968,000,000 |
| Total Cash Per Share | 3.203 |
| Total Debt | 32,349,999,104 |
| Total Revenue | 61,366,001,664 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 3.23 |
| Trailing Annual Dividend Yield | 0.01985249 |
| Trailing Eps | 6.69 |
| Trailing P E | 24.340807 |
| Trailing Peg Ratio | 1.4204 |
| Triggerable | 1 |
| Two Hundred Day Average | 184.2598 |
| Two Hundred Day Average Change | -21.4198 |
| Two Hundred Day Average Change Percent | -0.11624782 |
| Type Disp | Equity |
| Volume | 616,987 |
| Website | https://www.astrazeneca.com |
| Zip | CB2 0AA |